Sector
PharmaceuticalsOpen
₹1,911Prev. Close
₹1,906.05Turnover(Lac.)
₹2,643.52Day's High
₹1,926.95Day's Low
₹1,870.0552 Week's High
₹2,03052 Week's Low
₹1,244.45Book Value
₹196.99Face Value
₹1Mkt Cap (₹ Cr.)
29,516.73P/E
51.55EPS
36.83Divi. Yield
0.64Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 15.52 | 15.51 | 15.46 | 15.46 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 2,870.74 | 2,426.98 | 2,088.21 | 1,791 |
Net Worth | 2,886.26 | 2,442.49 | 2,103.67 | 1,806.46 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 2,189.87 | 1,891.99 | 1,640.74 | 1,250.13 |
yoy growth (%) | 15.74 | 15.31 | 31.24 | 6.42 |
Raw materials | -743.69 | -625.75 | -569.13 | -479.67 |
As % of sales | 33.96 | 33.07 | 34.68 | 38.36 |
Employee costs | -399.06 | -305.97 | -293.78 | -217.3 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 471.29 | 593.7 | 349.56 | 179.04 |
Depreciation | -71.28 | -67.35 | -65.09 | -55.94 |
Tax paid | -110.29 | -146.62 | -71.41 | -51.04 |
Working capital | 298.14 | 110.36 | 28.72 | 67.62 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.74 | 15.31 | 31.24 | 6.42 |
Op profit growth | -7.84 | 49.09 | 85.51 | -10.11 |
EBIT growth | -20.74 | 70.46 | 93.19 | -17.73 |
Net profit growth | -19.25 | 66.73 | 109.48 | -25.99 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 3,484.18 | 3,149.28 | 2,424.24 | 2,042.52 | 1,774.73 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,484.18 | 3,149.28 | 2,424.24 | 2,042.52 | 1,774.73 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 37.27 | 9.94 | 39.23 | 112.38 | 50.67 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,887.55 | 162.64 | 4,52,670.53 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,817.95 | 93.02 | 1,54,512 | 430 | 0.51 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,510.35 | 30.73 | 1,22,039.52 | 1,055.94 | 0.86 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,339.65 | 75.14 | 1,12,925.71 | 469 | 0.84 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,662.4 | 26.98 | 1,11,144.22 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Non-Exec. & Independent Dir.
Padmini Khare Kaicker
Non-Exec. & Independent Dir.
Sumit Bose
Non-Exec & Non-Independent Dir
Prashant Kumar.
Whole Time Director & CEO
Nikhil Chopra
Company Sec. & Compli. Officer
SANDEEP PHADNIS
Chairman & Independent Directo
Arun Duggal
Non Executive Director
GAURAV TREHAN
Non Executive Director
Akshay Tanna
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by J B Chemicals & Pharmaceuticals Ltd
Summary
J B Chemicals & Pharmaceuticals (JBC) was originally promoted and incorporated in Maharashtra by J B Mody as J B Mody Chemicals & Pharmaceuticals in December 18th, 1976. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceuticals formulations, herbal remedies and APIs. The company has manufacturing units at Thane, Belapur, Ankleshwar, Panoli and Daman. The bulk drug plant at Panoli and formulation plant at Daman became operational in Apr.95. Products like metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine) form a significant part of the companys sales. JBC has its subsidiaries namely Lekar Healthcare Ltd and J.B Life Science Overseas Ltd. JBC had a tie-up with Justesa Imagen, Spain, to manufacture and market radio diagnostics under the Trazograf brand name. JBC has also diversified into high-growth agro-based products by acquiring McDa Agro (MAL). The products manufactured by MAL complement fertilisers and increase crop productivity. It has entered into a MoU with GNFC to distribute these products locally. The pharmaceutical divisions of Ifiunik Pharmaceuticals and Unique Pharmaceutical Laboratories has been merged into the company with effect from April 2000.Unique Chemicals (A Division of the company) manufacturing and marketing Bulk Drugs has been awarded Certificate of Suitability to Europeon Pharmacopoeia Monograph for Nifedipine EP from Europeon Directorate for the Quality Medicines.In F
Read More
The J B Chemicals & Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1900.45 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of J B Chemicals & Pharmaceuticals Ltd is ₹29516.73 Cr. as of 22 Oct ‘24
The PE and PB ratios of J B Chemicals & Pharmaceuticals Ltd is 51.55 and 10.22 as of 22 Oct ‘24
The 52-week high/low is the highest and lowest price at which a J B Chemicals & Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of J B Chemicals & Pharmaceuticals Ltd is ₹1244.45 and ₹2030 as of 22 Oct ‘24
J B Chemicals & Pharmaceuticals Ltd's CAGR for 5 Years at 60.24%, 3 Years at 30.84%, 1 Year at 47.62%, 6 Month at 6.29%, 3 Month at 4.88% and 1 Month at -2.64%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice